Efficacy Studies of Corticosteroid Therapy in Community-Acquired Pneumonia
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00170196|
Recruitment Status : Completed
First Posted : September 15, 2005
Last Update Posted : September 29, 2008
The purpose of this study is to determine the efficacy of addition of corticosteroid therapy to antibiotics in patient admitted with Community-acquired pneumonia.
The hypothesis is: Prednisolone in combination with antibiotic treatments is effective in improving clinical outcome in patients hospitalized with CAP.
|Condition or disease||Intervention/treatment||Phase|
|Pneumonia||Drug: prednisone||Phase 3|
Community-acquired pneumonia (CAP) is a acute illness with a considerable morbidity and mortality, especially patients with severe CAP. In the past decennia, in spite of many investigations, little reduction is seen in morbidity an mortality. Corticosteroids have a immune-modulation effect, which is not completely elucidated. Most likely the immune modulation effect is due to down-regulation of pro-inflammatory cytokines. The use of corticosteroids next to antibiotics in CAP could lead to shorter time to clinical stability, length of stay and costs.
Comparison: Hospitalized patients with CAP treated with antibiotics and prednisolone versus hospitalized patients with cap treated with antibiotics and placebo
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||216 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||The CAPISCE-Trial: Community-Acquired Pneumonia; an Intervention Study With Corticosteroids|
|Study Start Date :||August 2005|
|Actual Primary Completion Date :||August 2008|
|Actual Study Completion Date :||September 2008|
- Clinical efficacy at the end of treatment
- Clinical efficacy at follow up
- Inflammation response (serummarkers)
- Length of Stay
- Time to clinical stability
- Time to defeverescence
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00170196
|Medisch Centrum Alkmaar|
|Alkmaar, Noord-Holland, Netherlands, 1815 JD|
|Principal Investigator:||Dominic Snijders, Drs||Pulmo Science|
|Study Director:||Wim G Boersma, dr||Pulmo Science|